713-928-2355
Menu
  • Home
  • Practice Areas
    • Personal Injury and Dangerous Devices
      • Philips® CPAP Recall
      • Knee Implant Failure
      • Elbow Implant Failure
      • Shoulder Replacement Lawsuit
      • 3M Earplug Lawsuit
    • Drug Injury
      • Purdue Opioid Claim
      • Invokana © and other SGLT2 Drugs Risk of Fournier Gangrene
      • Invokana® Increased Risk of Leg and Foot Amputations
      • Shingles Vaccine Lawsuit Zostavax®
    • Birth Injury
      • Depakote®
      • Dilantin®
      • Paxil®
      • Zofran®
      • Zoloft®
  • Maritime Injury
  • Buffalo Bayou or SJ River Claim
  • About
    • Victor Longo
  • Testimonials
  • Blog
  • Contact Us
Home / Uncategorized / Baxter Recalls Dialysis Solution after...

Baxter Recalls Dialysis Solution after Discovering Mold Contamination

  • Home

The U.S. Food and Drug Administration (FDA) has published details of a product recall affecting some dialysis patients.  The FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties.

Below is a press release posted on the FDA website regarding Baxter’s Nationwide Voluntary Recall of Premix Parenteral Nurtition.

FOR IMMEDIATE RELEASE – Baxter International Inc. announced today it has initiated a voluntary recall in the United States of two lots of CLINIMIX and one lot of CLINIMIX E Injection parenteral nutrition products to the user level due to complaints of particulate matter found in the products. If infused, particulate matter may result in blockages of blood vessels, which can result in stroke, heart attack, or damage to other organs such as the kidney or liver. There is also the possibility of allergic reactions, local irritation, and inflammation in tissues and organs. There have been no reported adverse events associated with this issue to date, and the root cause of this voluntary recall has been identified and resolved.

CLINIMIX (Amino Acid in Dextrose) Injection and CLINIMIX E (Amino Acid with Electrolytes in Dextrose with Calcium) Injections are premixed sterile intravenous (IV) parenteral nutrition products that come in multi-chambered containers and are used as a caloric component and as a protein source in a parenteral nutrition program. The affected product codes are 2B7729 (lot P287045, exp 06/14), 2B7717 (lot P275883, exp 10/13) and 2B7709 (lot P285122, exp 05/14). Affected products were distributed to healthcare centers and distributors in the United Sates.

Baxter has notified customers, who are being directed not to use product from the recalled lots. Customers should locate and remove all affected product from their facility. The affected lots were distributed to customers between May 2012 and October 2013. Unaffected lot numbers can continue to be used according to the instructions for use. Affected product should be returned to Baxter for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001, Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m., Central Time. Unaffected lots of product are available for replacement.

Consumers with questions regarding this recall can call Baxter at 1-800-422-9837, Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time, or e-mail Baxter at onebaxter@baxter.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Online:www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm
    Mail to address on the pre-addressed form.
  • Fax: 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

According to the CLINIMIX and CLINIMIX E product labeling, parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit. The use of a final filter is recommended during administration of all parenteral solutions where possible.

LikeBox

Phone: 713-928-2355
Fax: 1-713-923-1043
5728 Hood Street
Houston, TX 77023
Disclaimer/Warning This site is a public resource for general information. Nothing in this website should be considered legal advice. Communications by you through this website do not establish an attorney-client relationship. Our professional obligations require that before accepting any new client, we must determine whether any conflicts exist with current or former clients. To inquire about legal representation, please call or email us. An attorney-client relationship will not be created by placing a call or sending an email. Any medical decision is important. You should not stop taking any prescribed medication unless advised to do so by your doctor. Consult your doctor before making any medical decision and do not rely upon this website in making any medical decision. Attorney licensed in Texas. Attorney not certified by the Boards of Legal Specialization in any state. Not all states have board certifications. Attorney Victor Longo is responsible for the content of this advertisement. Representation is not available in all states and Longo Legal, PLLC is not accepting cases in all states. Longo Legal, PLLC may associate with other law firms in other states and jurisdictions as required. Cases will likely be referred to other lawyers for handling. © Copyright 2016 Longo Legal